Proterra (PTRAQ) 10-K/A 5 May 21 2020 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($)	5 Months Ended
	Dec. 31, 2020	Mar. 04, 2021	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	ArcLight Clean Transition Corp.
Document Type	10-K/A
Current Fiscal Year End Date	--12-31
Entity Public Float			$ 307,470,000
Amendment Flag	true
Amendment Description	References throughout this Amendment No. 1 to the Annual Report on Form 10-K to “we,” “us,” the “Company” or “our company” are to ArcLight Clean Transition Corp., unless the context otherwise indicates. This Amendment No. 1 (“Amendment No. 1”) to the Annual Report on Form 10-K/A amends the Annual Report on Form 10-K of ArcLight Clean Transition Corp. for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021 (the “Original Filing”), the Company’s previously issued unaudited financial statements as of September 30, 2020 and for the period from July 28, 2020 (inception) to September 30, 2020, which were included in the Company’s Quarterly Report on Form 10-Q for such period filed with the SEC on November 16, 2020 (the “Quarterly Report”) and the Company’s opening balance sheet as of September 25, 2020 which was included in the Company’s 8-K filing on October 1, 2020. On April 12, 2021, the staff of the SEC (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”) (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on September 25, 2020, our warrants were accounted for as equity within our balance sheet, and after discussion and evaluation, including with our independent auditors, we have concluded that our warrants should be presented as liabilities with subsequent fair value remeasurement. Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued financial statements for the periods beginning with the period from July 28, 2020 through December 31, 2020 and for the period from July 28, 2020 (inception) to September 30, 2020 (collectively, the “Affected Periods”) should be restated because of a misapplication in the guidance around accounting for certain of our outstanding warrants to purchase ordinary shares (the “Warrants”) and should no longer be relied upon. Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. We reassessed our accounting for Warrants issued on September 25, 2020, in light of the SEC Staff’s published views. Based on this reassessment, we determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in our Statement of Operations each reporting period. We are filing this Amendment No. 1 to include additional risk factors under Item 1A and to revise the Management’s Discussion and Analysis of Financial Condition and Results of Operation described in Item 7 and the Financial Statements and Supplementary Data described in Item 8, which financial statements and supplementary data give effect to the change in accounting for the Warrants as disclosed in the Original Filing. The change in accounting for the Warrants did not have any impact on our liquidity, cash flows, revenues or costs of operating our business and the other non-cash adjustments to the Financial Statements in the Affected Periods or in any of the periods included in Item 8, Financial Statements and Supplementary Data in this filing. The change in accounting for the Warrants does not impact the amounts previously reported for the Company’s cash and cash equivalents, operating expenses or total cash flows from operations for any of these periods. See Note 2 to the Notes to Financial Statements included in Part II, Item 8 of this Amendment No. 1 for additional information on the restatements and the related financial statement effects. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Item 1A, Risk Factors, is hereby amended to add additional risk factors, and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operation, Item 8, Financial Statements and Supplementary Data, and Item 9A, Controls and Procedures, of the Original Filing are hereby amended and restated in their entirety. This Amendment No. 1 should be read in conjunction with the Original Filing and with our filings with the SEC subsequent to the Original Filing. This Amendment No. 1 does not reflect events occurring after the filing of the Original Filing, and, except as described above, does not modify or update any other disclosures in the Original Filing.
Entity Central Index Key	0001820630
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Document Transition Report	false
Entity File Number	001-39546
Entity Incorporation, State or Country Code	E9
Entity Interactive Data Current	Yes
Class A Ordinary shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		27,750,000
Class B Ordinary shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		6,937,500

Balance Sheet

Balance Sheet	Dec. 31, 2020USD ($)
Current assets:
Cash	$ 873,882
Prepaid expenses	404,203
Total current assets	1,278,085
Investments held in Trust Account	277,548,542
Total Assets	278,826,627
Current liabilities:
Accounts payable	2,569
Accrued expenses	1,205,393
Total current liabilities	1,207,962
Deferred underwriting commissions	9,712,500
Derivative warrant liabilities	49,310,000
Total liabilities	60,230,462
Commitments and Contingencies
Class A ordinary shares; 21,359,616 shares subject to possible redemption at $10.00 per share	213,596,160
Shareholders’ Equity:
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 6,390,384 shares issued and outstanding (excluding 21,359,616 shares subject to possible redemption)	639
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 6,937,500 shares issued and outstanding	694
Additional paid-in capital	38,706,614
Accumulated deficit	(33,707,942)
Total shareholders’ equity	5,000,005
Total Liabilities and Shareholders’ Equity	$ 278,826,627

Balance Sheet (Parentheticals)

Balance Sheet (Parentheticals)	Dec. 31, 2020$ / sharesshares
Subject to possible redemption	21,359,616
Subject to possible redemption, per share (in Dollars per share) | $ / shares	$ 10
Preferred stock par value (in Dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Ordinary shares
Common stock par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	500,000,000
Common stock, shares issued	6,390,384
Common stock, shares outstanding	6,390,384
Class B Ordinary shares
Common stock par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	50,000,000
Common stock, shares issued	6,937,500
Common stock, shares outstanding	6,937,500

Statement of Operations

Statement of Operations	5 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Income Statement [Abstract]
General and administrative expenses	$ 1,332,873
Loss from operations	(1,332,873)
Other (expense) income
Change in fair value of derivative warranty liabilities	(31,750,900)
Financing costs – warrant liabilities	(672,711)
Interest income	48,542
Total other (expense) income	(32,375,069)
Net loss	$ (33,707,942)
Weighted average shares outstanding of Redeemable Class A common stock subject to redemption, basic and diluted (in Shares) | shares	25,913,041
Basic and diluted net income per share, common stock subject to redemption (in Dollars per share) | $ / shares
Weighted average shares outstanding of Non-Redeemable Class A and Class B common stock, basic and diluted (in Shares) | shares	8,643,813
Basic and diluted net loss per share, common stock (in Dollars per share) | $ / shares	$ (3.90)

Statement of Changes in Shareho

Statement of Changes in Shareholders’ Equity - 5 months ended Dec. 31, 2020 - USD ($)	Ordinary Shares Class A	Ordinary Shares Class B	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jul. 28, 2020
Balance (in Shares) at Jul. 28, 2020
Issuance of Class B ordinary shares to Sponsor		$ 694	24,306		25,000
Issuance of Class B ordinary shares to Sponsor (in Shares)		6,937,500
Sale of units in initial public offering, gross	$ 2,775		266,137,725		266,140,500
Sale of units in initial public offering, gross (in Shares)	27,750,000
Offering costs			(15,211,793)		(15,211,793)
Sale of private placement warrants to Sponsor in private placement			1,350,400		1,350,400
Shares subject to possible redemption	$ (2,136)		(213,594,024)		(213,596,160)
Shares subject to possible redemption (in Shares)	(21,359,616)
Net loss				(33,707,942)	(33,707,942)
Balance at Dec. 31, 2020	$ 639	$ 694	$ 38,706,614	$ (33,707,942)	$ 5,000,005
Balance (in Shares) at Dec. 31, 2020	6,390,384	6,937,500

Statement of Cash Flows

Statement of Cash Flows	5 Months Ended
	Dec. 31, 2020USD ($)
Cash Flows from Operating Activities:
Net loss	$ (33,707,942)
Adjustments to reconcile net loss to net cash used in operating activities:
General and administrative expenses paid by related party in exchange for issuance of Class B ordinary shares	25,000
General and administrative expenses paid by related party	30,387
Change in fair value of derivative warrant liabilities	31,750,900
Financing costs – warrant liabilities	672,711
Interest income	(48,542)
Changes in operating assets and liabilities:
Prepaid expenses	(404,203)
Accounts payable	2,569
Accrued expenses	1,135,393
Net cash used in operating activities	(543,727)
Cash Flows from Investing Activities:
Cash deposited in Trust Account	(277,500,000)
Net cash used in investing activities	(277,500,000)
Cash Flows from Financing Activities:
Proceeds from note payable to related party	100
Proceeds received from initial public offering, gross	277,500,000
Proceeds received from private placement	7,550,000
Offering costs paid	(5,978,903)
Repayment of note payable to related parties	(153,588)
Net cash provided by financing activities	278,917,609
Net increase in cash	873,882
Cash - beginning of the period
Cash - ending of the period	873,882
Supplemental disclosure of noncash investing and financing activities:
Offering costs included in accrued expenses	70,000
Offering costs included in note payable – related party	123,101
Deferred underwriting commissions	9,712,500
Original Value of Class A ordinary shares subject to possible redemption	211,817,230
Change in value of Class A ordinary shares subject to possible redemption	$ 1,778,930

Description of Organization, Bu

Description of Organization, Business Operations and Basis of Presentation	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Description of Organization, Business Operations and Basis of Presentation	Note 1—Description of Organization, Business Operations and Basis of Presentation ArcLight Clean Transition Corp. (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on July 28, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). As of December 31, 2020, the Company had not yet commenced operations. All activity for the period from July 28, 2020 (inception) through December 31, 2020 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”) and since the closing of the initial public offering, the search for a prospective initial Business Combination. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is ArcLight CTC Holdings, L.P., a Delaware limited partnership (“Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on September 22, 2020. On September 25, 2020, the Company consummated its Initial Public Offering of 25,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $250.0 million, and incurring offering costs of approximately $14.4 million, inclusive of approximately $8.8 million in deferred underwriting commissions (Note 7). On September 29, 2020, the Company issued an additional 2,750,000 units (the “Over-Allotment Units”) pursuant to the partial exercise by the underwriters of their over-allotment option in connection with the Initial Public Offering (the “Over-Allotment”). The Over-Allotment Units were priced at $10.00 per Unit, generating total gross proceeds of $27.5 million and incurring additional offering costs of approximately $1.5 million, inclusive of approximately $1.0 million in deferred underwriting commissions. Simultaneously with the closing of the Initial Public Offering on September 25, 2020, the Company consummated the private placement (“Private Placement”) of 7,000,000 private placement warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant with the Sponsor, generating gross proceeds of $7.0 million (Note 5). Concurrently with the consummation of the Over-Allotment on September 29, 2020, the Sponsor also purchased an additional 550,000 Private Placement Warrants, generating gross proceeds of approximately $0.6 million. Upon the closing of the Initial Public Offering and the Private Placement on September 25, 2020, $250.0 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. In connection with the consummation of the Over-Allotment on September 29, 2020, an additional amount of $27.5 million ($10.00 per Unit), for a total of approximately $277.5 million, was placed in the Trust Account. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended, or the Investment Company Act. The Company will provide its holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). These Public Shares will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares prior to the Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares (as defined in Note 6) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company has agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, executive officers, directors and director nominees agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or September 25, 2022 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Basis of Presentation The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. As described in Note 2—Restatement of Previously Issued Financial Statements, the Company’s consolidated financial statements for the period from July 28, 2020 (inception) through December 31, 2020, and for the period from July 28, 2020 through September 30, 2020 (collectively, the “Affected Periods”), are restated in this Annual Report on Form 10-K/A (Amendment No. 1) (this “Annual Report”) to correct the misapplication of accounting guidance related to the Company’s warrants in the Company’s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as “Restated” in the audited and unaudited condensed financial statements and accompanying notes, as applicable. See Note 2—Restatement of Previously Issued Financial Statements for further discussion. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Going Concern As of December 31, 2020, the Company had $0.9 million in its operating bank account. The Company’s liquidity needs up to September 25, 2020 had been satisfied through a payment of $25,000 from the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of approximately $154,000 (see Note 6) to the Company, and the net proceeds from the consummation of the Private Placement not held in the Trust Account. The Note was repaid in full on October 1, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s officers, directors and Initial Shareholders may, but are not obligated to, provide the Company Working Capital Loans (see Note 6). To date, there were no amounts outstanding under any Working Capital Loans. In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Basis of Presentation – Going Concern,” management has determined that the anticipated cash requirements in the next twelve months raise substantial about the Company’s ability to continue as a going concern until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate, September 25, 2022. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern . Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Restatement of Financial Statem

Restatement of Financial Statements	5 Months Ended
	Dec. 31, 2020
Condensed Financial Information Disclosure [Abstract]
Restatement of Financial Statements	Note 2—Restatement of Financial Statements In April 2021, the Company concluded that, because of a misapplication of the accounting guidance related to its Public and Private Placement warrants the Company issued in September 2020, the Company’s previously issued financial statements for the Affected Periods should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods included in this Annual Report. On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”) (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on September 25, 2020 and September 29, 2020 Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for Warrants issued on September 25, 2020 and September 29, 2020, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company Statement of Operations each reporting period. Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued financial statements for the periods beginning with the period from July 28, 2020 (inception) through December 31, 2020 (collectively, the “Affected Periods”) should be restated because of a misapplication in the guidance around accounting for certain of our outstanding warrants to purchase ordinary shares (the “Warrants”) and should no longer be relied upon. The Warrants were issued in connection with the Company’s Initial Public Offering of 25,000,000 Units and the sale of Private Placement warrants completed on September 25, 2020. Each Unit consists of one of the Company’s Class A ordinary shares, $0.0001 par value, and one-half of one redeemable warrant. Each whole Warrant entitles the holder to purchase one of Class A ordinary share at a price of $11.50 per share. The Warrants will expire worthless five years from the date of completion of our initial business combination. The material terms of the warrants are more fully described in Note 8—Derivative Warrant Liabilities. See revised Footnote 9 – Fair Value Measurements. Impact of the Restatement The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities The tables below present the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported financial statements as of and for the year ended December 31, 2020. As of December 31, 2020 As Previously Reported Restatement Adjustment As Restated Balance Sheet Total assets $ 278,826,627 $ - $ 278,826,627 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,207,962 $ - $ 1,207,962 Deferred underwriting commissions 9,712,500 - 9,712,500 Derivative warrant liabilities - 49,310,000 49,310,000 Total liabilities 10,920,462 49,310,000 60,230,462 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 262,906,160 (49,310,000 ) 213,596,160 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 146 493 639 Class B ordinary shares - $0.0001 par value 694 - 694 Additional paid-in-capital 6,283,496 32,423,118 38,706,614 Accumulated deficit (1,284,331 ) (32,423,611 ) (33,707,942 ) Total shareholders’ equity 5,000,005 - 5,000,005 Total liabilities and shareholders’ equity $ 278,826,627 $ - $ 278,826,627 Period From July 28, 2020 (inception) Through December 31, 2020 As Previously Reported Restatement Adjustment As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (1,332,873 ) $ - $ (1,332,873 ) Other (expense) income: Change in fair value of derivative warrant liabilities - (31,750,900 ) (31,750,900 ) Financing costs - derivative warrant liabilities - (672,711 ) (672,711 ) Interest earned on investments held in Trust Account 48,542 - 48,542 Total other (expense) income 48,542 (32,423,611 ) (32,375,069 ) Net loss $ (1,284,331 ) $ (32,423,611 ) $ (33,707,942 ) Basic and Diluted weighted-average Class A ordinary shares outstanding 26,276,074 - 25,913,041 Basic and Diluted net loss per Class A share $ 0.00 - $ 0.00 Basic and Diluted weighted-average Class B ordinary shares outstanding 7,561,720 - 8,643,813 Basic and Diluted net loss per Class B share $ (0.18 ) - $ (3.90 ) Period From July 28, 2020 (inception) Through December 31, 2020 As Previously Restatement As Restated Statement of Cash Flows Net loss $ (1,284,331 ) $ (32,423,611 ) $ (33,707,942 ) Adjustment to reconcile net loss to net cash used in operating activities 740,604 32,423,611 33,164,215 Net cash used in operating activities (543,727 ) - (543,727 ) Net cash used in investing activities (277,500,000 ) - (277,500,000 ) Net cash provided by financing activities 278,917,609 - 278,917,609 Net change in cash $ 873,882 $ - $ 873,882 In addition, the impact to the balance sheet dated September 25, 2020, filed on Form 8-K on October 1, 2020 related to the impact of accounting for the public and private warrants as liabilities at fair value resulted in a $16.1 million increase to the derivative warrant liabilities line item at September 25. 2020 and offsetting decrease to the Class A common stock subject to possible redemption mezzanine equity line item. There is no change to total stockholders’ equity at the reported balance sheet date. As of September 25, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 252,456,400 $ - $ 252,456,400 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,109,161 $ - $ 1,109,161 Deferred underwriting commissions 8,750,000 - 8,750,000 Derivative warrant liabilities - 16,090,000 16,090,000 Total liabilities 9,859,161 16,090,000 25,949,161 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 237,597,230 (16,090,000 ) 221,507,230 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 124 161 285 Class B ordinary shares - $0.0001 par value 719 - 719 Additional paid-in-capital 5,039,923 672,550 5,712,473 Accumulated deficit (40,757 ) (672,711 ) (713,468 ) Total shareholders’ equity 5,000,009 - 5,000,009 Total liabilities and shareholders’ equity $ 252,456,400 $ - $ 252,456,400

Summary of Significant Accounti

Summary of Significant Accounting Policies	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies Use of Estimates The preparation of financial statement in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020, the Company had $277.5 million in cash equivalents held in money market funds. Investments Held in Trust Account The Company’s portfolio of investments is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in net gain on investments, dividends and interest held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000, and investments held in Trust Account. At December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020, the carrying values of cash and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in money market funds that invest in U.S. government securities, or a combination thereof. The fair value for trading securities is determined using quoted market prices in active markets. Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company accounts for its 21,425,000 warrants to purchase ordinary shares issued in connection with its Initial Public Offering (13,875,000) and Private Placement (7,550,000) as derivative warrant liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued by the Company in connection with the Public Offering and Private Placement has been estimated using Monte-Carlo simulations at each measurement date. Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering and were charged to shareholders’ equity or written off to the statement of operations upon the completion of the Initial Public Offering. The portion of the offering costs related to the issuance of the public and private warrants was expensed and included in the statement of operations as a financing costs – warrant liabilities. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, 21,359,616 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “ Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts were accrued for interest and penalties for the period from July 28, 2020 (inception) through December 31, 2020 The Company may be subject to potential examination by U.S. federal, U.S. state or foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, deferred tax assets and income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net Loss Per Ordinary Share Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Public Offering and Private Placement to purchase an aggregate of 21,425,000 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The Company’s statement of operations includes a presentation of income (loss) per share for Redeemable Class A Common Stock in a manner similar to the two-class method of income (loss) per share. Net income per common share, basic and diluted, for Redeemable Class A Common Stock is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Non-Redeemable Class A and Class B Common Stock is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to Redeemable Class A Common Stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-Redeemable Class A and Class B Common Stock includes Founder Shares and non-redeemable shares of common stock as these shares do not have any redemption features. Non-Redeemable Class A and Class B Common Stock participates in the income or loss on marketable securities based on non-redeemable common stock shares’ proportionate interest. The basic and diluted loss per common share is calculated as follows. For The Period From July 28, 2020 (inception) through December 31, 2020 Class A Common stock subject to possible redemption Numerator: Earnings allocable to Common stock subject to possible redemption Income from investments held in Trust Account $ 37,362 Less: Company’s portion available to be withdrawn to pay taxes - Net income attributable $ 37,362 Denominator: Weighted average Class A common stock subject to possible redemption Basic and diluted weighted average shares outstanding 25,913,041 Basic and diluted net income per share $ 0.00 Non-Redeemable Common Stock Numerator: Net Loss minus Net Earnings Net loss $ (33,707,942 ) Less: Net income allocable to Class A common stock subject to possible redemption 37,362 Non-redeemable net loss $ (33,745,304 ) Denominator: weighted average Non-redeemable common stock Basic and diluted weighted average shares outstanding, Non-redeemable common stock 8,643,813 Basic and diluted net loss per share, Non-redeemable common stock $ (3.90 ) Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a material effect on the Company’s financial statements.

Initial Public Offering

Initial Public Offering	5 Months Ended
	Dec. 31, 2020
Initial Public Offering Disclosure Textblock [Abstract]
Initial Public Offering	Note 4—Initial Public Offering On September 25, 2020, the Company consummated its Initial Public Offering of 25,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250.0 million, and incurring offering costs of approximately $14.4 million, inclusive of approximately $8.8 million in deferred underwriting commissions. On September 29, 2020, the Company issued an additional 2,750,000 Over-Allotment Units pursuant to the partial exercise by the underwriters of their over-allotment option in connection with the Initial Public Offering. The Over-Allotment Units were priced at $10.00 per Unit, generating total gross proceeds of $27.5 million and incurring additional offering costs of approximately $1.5 million, inclusive of approximately $1.0 million in deferred underwriting commissions. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8).

Private Placement

Private Placement	5 Months Ended
	Dec. 31, 2020
Private Placement Disclosure [Abstract]
Private Placement	Note 5—Private Placement Simultaneously with the closing of the Initial Public Offering on September 25, 2020, the Company consummated the Private Placement of 7,000,000 Private Placement Warrants, at a price of $1.00 per Private Placement Warrant with the Sponsor, generating gross proceeds of $7.0 million. Concurrently with the consummation of the Over-Allotment on September 29, 2020, the Sponsor also purchased an additional 550,000 Private Placement Warrants, generating gross proceeds of approximately $0.6 million. Each whole Private Placement Warrant is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable for cash and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination.

Related Party Transactions

Related Party Transactions	5 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 6—Related Party Transactions Founder Shares On August 3, 2020, the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 8,625,000 Class B ordinary shares (the “Founder Shares”). On September 3, 2020, the Sponsor transferred 35,000 Founder Shares to each of Arno Harris, Ja-Chin Audrey Lee, Brian Goncher and Steven Berkenfeld, the Company’s independent director nominees. On September 18, 2020, the Sponsor irrevocably surrendered to the Company for cancellation and for nil consideration 1,437,500 Class B ordinary shares, resulting in 7,187,500 Class B ordinary shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share surrender. The Sponsor agreed to forfeit up to an aggregate of 937,500 Founder Shares to the extent that the option to purchase additional units is not exercised in full by the underwriters, so that the Founder Shares will represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters partially exercised their over-allotment option on September 29, 2020, with the remaining portion of the over-allotment option expiring at the conclusion of the 45-day option period. As a result of the expiration of the over-allotment option, an aggregate of 250,000 Founder Shares were forfeited by the Sponsor. The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. Related Party Loans On August 3, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is non-interest bearing, unsecured and due upon the closing of the Initial Public Offering. As of December 31, 2020, the Company borrowed approximately $154,000 under the Note. The Note was repaid in full on October 1, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans. Administrative Services Agreement The Company entered into an agreement that provides that, commencing on the date that the Company’s securities are first listed on NASDAQ through the earlier of consummation of the initial Business Combination and the liquidation, the Company may pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to the Company. In addition, the Sponsor, officers and directors, or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Company’s audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made using funds held outside the Trust Account. The Company incurred approximately $33,000 in expenses in connection with such services during the period from July 28, 2020 through December 31, 2020 as reflected in the accompanying statement of operations. As of December 31, 2020, the Company had nil in accrued expenses—related party in connection with such services .

Commitments and Contingencies

Commitments and Contingencies	5 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7—Commitments and Contingencies Registration and Shareholder Rights The holders of the Founder Shares, Private Placement Warrants, and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of this prospectus to purchase up to 3,750,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. The underwriters partially exercised their over-allotment option on September 29, 2020 to purchase an additional 2,750,000 Over-Allotment Units. The remaining unexercised over-allotment option expired unexercised on November 6, 2020. In connection with the consummation of the Initial Public Offering on September 25, 2020, the underwriters were entitled to an underwriting discount of $0.20 per unit, or $5.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $8.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. On September 29, 2020, the underwriters were entitled to an additional underwriting discount of approximately $0.6 million paid upon the closing of the Over-Allotment, and an additional deferred underwriting commissions of approximately $1.0 million. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Contingent Liabilities The Company is involved in legal proceedings, alleging that the Company their fiduciary duties by omitting allegedly material information in the Registration Statement filed by the Company on Form S-4 on February 3, 2021 in connection with the Proposed Transaction, and that the Company aided and abetted such alleged breaches of fiduciary duty. As relief, the complaints seek, among other things, an injunction barring the Company from proceeding with the Proposed Transaction, or, alternatively, rescission of the Proposed Transaction in the event that it is consummated, as well as unspecified costs and attorneys’ fees. The Company believes these lawsuits are without merit. the outcomes of these proceedings and lawsuits cannot be predicted with certainty. The Company does not believe that any of the pending legal proceedings and lawsuits are reasonably likely to have a material adverse effect on our financial position, results of operations or cash flows.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	5 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Warrant Liabilities	Note 8—Derivative Warrant Liabilities As of December 31, 2020, the Company has 13,875,000 and 7 ,550,000 Public Warrants and Private Placement Warrants, respectively, outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under certain circumstances). The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC and have an effective registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60 th The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the Initial Shareholders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00: ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; and ● if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and ● if the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of our Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment). In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Shareholders_ Equity

Shareholders’ Equity	5 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Shareholders’ Equity	Note 9—Shareholders’ Equity Class A Ordinary Shares Class B Ordinary Shares Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. The Class B ordinary shares will automatically convert into Class A ordinary shares, which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions if the Company does not consummate an initial Business Combination, at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities (as defined herein) or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any member of the management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one. Preference Shares

Fair Value Measurements

Fair Value Measurements	5 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10—Fair Value Measurements The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2020 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. Quoted Prices in Significant Other Significant Other Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account $ 277,547,390 $ - $ - Liabilities: Derivative warrant liabilities – public warrants $ 31,930,000 $ - $ - Derivative warrant liabilities – private warrants $ - $ - $ 17,380,000 The remainder of the balance in Investments held in Trust Account, approximately $1,000, is comprised of cash equivalents. Level 1 instruments include investments in cash, money market funds and U.S. Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in November 2020, when the Public Warrants were separately listed and traded. The changes in Level 3 liability measured at fair value for the fiscal year ended December 31, 2020 was solely due to the change in the fair value of the warrant liability reflected on the statement of operations. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs. The Company utilizes a binomial Monte-Carlo simulation to estimate the fair value of the warrants at each reporting period, with changes in fair value recognized in the statement of operations. The Company recognized $16,090,000 for the derivative warrant liabilities upon their issuance on September 25, 2020. For the period from July 28, 2020 (inception) through December 31, 2020, the Company recognized a charge to the statement of operations resulting from an increase in the fair value of liabilities of $33,220,000 presented as change in fair value of derivative warrant liabilities on the accompanying statement of operations. The estimated fair value of the derivative warrant liabilities is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs as their measurement dates: As of As of Strike price $ 10.00 $ 10.04 Contractual term (years) 1.0 1.0 Volatility 15.00 % 22.00 % Risk-free interest rate 37.00 % 0.38 % Dividend yield(per share) 0.0 % 0.0 % The change in the fair value of the derivative warrant liabilities for the period from July 22, 2020 (inception) through December 31, 2020 is summarized as follows: Derivative warrant liabilities at July 3, 2020 (inception) $ - Issuance of Public and Private Warrants 16,090,000 Additional warrant liabilities 1,469,100 Change in fair value of derivative warrant liabilities 31,750,900 Derivative warrant liabilities at December 31, 2020 $ 49,310,000

Subsequent Events

Subsequent Events	5 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 11—Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date the financial statements are issued, require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed, except as disclosed below On January 11, 2021, the Company entered into an Agreement and Plan of Merger with Proterra Inc, a Delaware corporation (“Proterra”). The Merger Agreement and the transactions contemplated thereby were approved by the boards of directors of each of the Company and Proterra. The Business Combination The Merger Agreement provides for, among other things, the following: (i) the Company will become a Delaware corporation (the “Domestication”), (ii) following the Domestication, a subsidiary of the Company will merge with and into Proterra, with Proterra as the surviving company in the merger and continuing as a wholly-owned subsidiary of the Company (the “Merger”) and, in connection with the Merger, (iii) the Company’s name will be changed to Proterra Inc. The Domestication, the Merger and the other transactions contemplated by the Merger Agreement are referred to as the “Business Combination”. The Business Combination is expected to close in the second quarter of 2021, following the receipt of the required approval by the Company’s stockholders and the fulfillment of other customary closing conditions. Business Combination Consideration In the Merger, each share of common stock of Proterra, other than shares to be cancelled or dissenting shares, will be converted into the right to receive 0.8925 shares of ArcLight Common Stock. In the event that the closing sale price of ArcLight Common Stock exceeds certain price thresholds for 20 out of any 30 consecutive trading days during the first five years following the closing of the Business Combination, up to an additional 22,809,500 shares of ArcLight Common Stock may be issued to the parties that were holders of Proterra Common Stock immediately prior to the closing of the Business Combination. PIPE Financing (Private Placement) Concurrently with the execution of the Merger Agreement, the Company entered into subscription agreements with certain investors, pursuant to which they agreed to subscribe for and purchase, , immediately following the closing of the Merger, an aggregate of 41,500,000 shares of the Company Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $415,000,000 (the “PIPE Financing”). The closing of the PIPE Financing is contingent upon, among other things, the substantially concurrent consummation of the Business Combination. The Subscription Agreements provide that the Company will grant the investors in the PIPE Financing certain customary registration rights. Sponsor Support Agreement Concurrently with the execution of the Merger Agreement, the Sponsor, and other holders of Class B ordinary shares of ArcLight entered into a Sponsor Support Agreement (the “Sponsor Support Agreement”) with the Company and Proterra, pursuant to which the Sponsor and such holders agreed to, among other things, (i) vote at any meeting of the shareholders of the Company all of their ordinary shares held of record or thereafter acquired in favor of the proposals being considered in connection with the Business Combination, (ii) be bound by certain other covenants and agreements related to the Business Combination and (iii) be bound by certain transfer restrictions with respect to such securities, prior to the closing of the Business Combination, in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement. Sponsor Letter Agreement Concurrently with the execution of the Merger Agreement, the Sponsor entered into the Sponsor Letter Agreement (the “Sponsor Letter Agreement”), pursuant to which the parties agreed (i) to certain vesting and forfeiture terms with respect to 10% of the Company’s Common Stock beneficially owned by the Sponsor immediately following the closing, (ii) to certain lock-up provisions with respect to shares of Company Common Stock following the Merger (which provisions were subsequently amended on February 2, 2021) and (iii) to cause the Company’s designee to the ArcLight board of directors to resign in the event the Sponsor disposes of 50% or more of the ArcLight Common Stock held beneficially by the Sponsor as of the closing of the Business Combination. Amended and Restated Registration Rights Agreement At the closing of the Business Combination, Proterra, the Sponsor and certain stockholders of Proterra will enter into an amended and restated registration rights agreement pursuant to which, among other things, the parties thereto will be granted certain customary registrant rights with respect to shares of Proterra Common Stock.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	5 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Note 12 — Quarterly Financial Information (Unaudited) The following tables contain unaudited consolidated quarterly financial information for the quarterly period ended September 30, 2020 that has been updated to reflect the restatement and revision of the Company’s consolidated financial statements as described in Note 2—Restatement of Previously Issued Financial Statements. The restatement and revision had no impact net loss, net cash flows from operating, investing or financing activities. The Company has not amended its previously filed Quarterly Report on Form 10-Q for the Affected Period. The financial information that has been previously filed or otherwise reported for the Affected Period is superseded by the information in this Annual Report, and the financial statements and related financial information for the Affected Period contained in such previously filed report should no longer be relied upon. As of September 30, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 279,941,343 $ - $ 279,941,343 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,102,095 $ - $ 1,102,095 Deferred underwriting commissions 9,712,500 - 9,712,500 Derivative warrant liabilities - 16,350,000 16,350,000 Total liabilities 10,814,595 16,350,000 27,164,595 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 264,126,740 (16,350,000 ) 247,776,740 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 134 163 297 Class B ordinary shares - $0.0001 par value 694 - 694 Additional paid-in-capital 5,062,928 (536,552 ) 4,526,376 Accumulated deficit (63,748 ) 536,389 472,641 Total shareholders’ equity 5,000,008 - 5,000,008 Total liabilities and shareholders’ equity $ 279,941,343 $ - $ 279,941,343 Period From July 28, 2020 (inception) Through September 30, 2020 As Previously Restatement As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (63,748 ) $ - $ (63,748 ) Other (expense) income: Change in fair value of warrant liabilities - 1,209,100 1,209,100 Financing costs - derivative warrant liabilities - (672,711 ) (672,711 ) Total other (expense) income - 536,389 536,389 Net loss $ (63,748 ) $ 536,389 $ 472,641 Basic and Diluted weighted-average Class B ordinary shares outstanding 7,066,920 - 7,275,953 Basic and Diluted net loss per Class B share $ (0.01 ) - $ 0.06 Period From July 28, 2020 (inception) Through September 30, 2020 As Previously Restatement As Restated Statement of Cash Flows Net loss $ (63,748 ) $ 536,389 $ 472,641 Adjustment to reconcile net loss to net cash used in operating activities 48,298 (536,389 ) (488,091 ) Net cash used in operating activities (15,450 ) - (15,450 ) Net cash used in investing activities (277,500,000 ) - (277,500,000 ) Net cash provided by financing activities 279,500,100 - 279,500,100 Net change in cash $ 1,984,650 $ - $ 1,984,650

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statement in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020, the Company had $277.5 million in cash equivalents held in money market funds.
Investments Held in Trust Account	Investments Held in Trust Account The Company’s portfolio of investments is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in net gain on investments, dividends and interest held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000, and investments held in Trust Account. At December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020, the carrying values of cash and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in money market funds that invest in U.S. government securities, or a combination thereof. The fair value for trading securities is determined using quoted market prices in active markets.
Derivative warrant liabilities	Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company accounts for its 21,425,000 warrants to purchase ordinary shares issued in connection with its Initial Public Offering (13,875,000) and Private Placement (7,550,000) as derivative warrant liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued by the Company in connection with the Public Offering and Private Placement has been estimated using Monte-Carlo simulations at each measurement date.
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering and were charged to shareholders’ equity or written off to the statement of operations upon the completion of the Initial Public Offering. The portion of the offering costs related to the issuance of the public and private warrants was expensed and included in the statement of operations as a financing costs – warrant liabilities.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, 21,359,616 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “ Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts were accrued for interest and penalties for the period from July 28, 2020 (inception) through December 31, 2020 The Company may be subject to potential examination by U.S. federal, U.S. state or foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, deferred tax assets and income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Loss Per Ordinary Share	Net Loss Per Ordinary Share Net income (loss) per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Public Offering and Private Placement to purchase an aggregate of 21,425,000 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The Company’s statement of operations includes a presentation of income (loss) per share for Redeemable Class A Common Stock in a manner similar to the two-class method of income (loss) per share. Net income per common share, basic and diluted, for Redeemable Class A Common Stock is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Non-Redeemable Class A and Class B Common Stock is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to Redeemable Class A Common Stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-Redeemable Class A and Class B Common Stock includes Founder Shares and non-redeemable shares of common stock as these shares do not have any redemption features. Non-Redeemable Class A and Class B Common Stock participates in the income or loss on marketable securities based on non-redeemable common stock shares’ proportionate interest. The basic and diluted loss per common share is calculated as follows. For The Period From July 28, 2020 (inception) through December 31, 2020 Class A Common stock subject to possible redemption Numerator: Earnings allocable to Common stock subject to possible redemption Income from investments held in Trust Account $ 37,362 Less: Company’s portion available to be withdrawn to pay taxes - Net income attributable $ 37,362 Denominator: Weighted average Class A common stock subject to possible redemption Basic and diluted weighted average shares outstanding 25,913,041 Basic and diluted net income per share $ 0.00 Non-Redeemable Common Stock Numerator: Net Loss minus Net Earnings Net loss $ (33,707,942 ) Less: Net income allocable to Class A common stock subject to possible redemption 37,362 Non-redeemable net loss $ (33,745,304 ) Denominator: weighted average Non-redeemable common stock Basic and diluted weighted average shares outstanding, Non-redeemable common stock 8,643,813 Basic and diluted net loss per share, Non-redeemable common stock $ (3.90 )
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a material effect on the Company’s financial statements.

Restatement of Financial Stat_2

Restatement of Financial Statements (Tables)	5 Months Ended
	Dec. 31, 2020
Condensed Financial Information Disclosure [Abstract]
Schedule of statements of balance sheet	As of December 31, 2020 As Previously Reported Restatement Adjustment As Restated Balance Sheet Total assets $ 278,826,627 $ - $ 278,826,627 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,207,962 $ - $ 1,207,962 Deferred underwriting commissions 9,712,500 - 9,712,500 Derivative warrant liabilities - 49,310,000 49,310,000 Total liabilities 10,920,462 49,310,000 60,230,462 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 262,906,160 (49,310,000 ) 213,596,160 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 146 493 639 Class B ordinary shares - $0.0001 par value 694 - 694 Additional paid-in-capital 6,283,496 32,423,118 38,706,614 Accumulated deficit (1,284,331 ) (32,423,611 ) (33,707,942 ) Total shareholders’ equity 5,000,005 - 5,000,005 Total liabilities and shareholders’ equity $ 278,826,627 $ - $ 278,826,627 As of September 25, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 252,456,400 $ - $ 252,456,400 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,109,161 $ - $ 1,109,161 Deferred underwriting commissions 8,750,000 - 8,750,000 Derivative warrant liabilities - 16,090,000 16,090,000 Total liabilities 9,859,161 16,090,000 25,949,161 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 237,597,230 (16,090,000 ) 221,507,230 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 124 161 285 Class B ordinary shares - $0.0001 par value 719 - 719 Additional paid-in-capital 5,039,923 672,550 5,712,473 Accumulated deficit (40,757 ) (672,711 ) (713,468 ) Total shareholders’ equity 5,000,009 - 5,000,009 Total liabilities and shareholders’ equity $ 252,456,400 $ - $ 252,456,400
Schedule of statements of operations	Period From July 28, 2020 (inception) Through December 31, 2020 As Previously Reported Restatement Adjustment As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (1,332,873 ) $ - $ (1,332,873 ) Other (expense) income: Change in fair value of derivative warrant liabilities - (31,750,900 ) (31,750,900 ) Financing costs - derivative warrant liabilities - (672,711 ) (672,711 ) Interest earned on investments held in Trust Account 48,542 - 48,542 Total other (expense) income 48,542 (32,423,611 ) (32,375,069 ) Net loss $ (1,284,331 ) $ (32,423,611 ) $ (33,707,942 ) Basic and Diluted weighted-average Class A ordinary shares outstanding 26,276,074 - 25,913,041 Basic and Diluted net loss per Class A share $ 0.00 - $ 0.00 Basic and Diluted weighted-average Class B ordinary shares outstanding 7,561,720 - 8,643,813 Basic and Diluted net loss per Class B share $ (0.18 ) - $ (3.90 )
Schedule of statements of cash flows	Period From July 28, 2020 (inception) Through December 31, 2020 As Previously Restatement As Restated Statement of Cash Flows Net loss $ (1,284,331 ) $ (32,423,611 ) $ (33,707,942 ) Adjustment to reconcile net loss to net cash used in operating activities 740,604 32,423,611 33,164,215 Net cash used in operating activities (543,727 ) - (543,727 ) Net cash used in investing activities (277,500,000 ) - (277,500,000 ) Net cash provided by financing activities 278,917,609 - 278,917,609 Net change in cash $ 873,882 $ - $ 873,882

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of basic and diluted loss per common share	For The Period From July 28, 2020 (inception) through December 31, 2020 Class A Common stock subject to possible redemption Numerator: Earnings allocable to Common stock subject to possible redemption Income from investments held in Trust Account $ 37,362 Less: Company’s portion available to be withdrawn to pay taxes - Net income attributable $ 37,362 Denominator: Weighted average Class A common stock subject to possible redemption Basic and diluted weighted average shares outstanding 25,913,041 Basic and diluted net income per share $ 0.00 Non-Redeemable Common Stock Numerator: Net Loss minus Net Earnings Net loss $ (33,707,942 ) Less: Net income allocable to Class A common stock subject to possible redemption 37,362 Non-redeemable net loss $ (33,745,304 ) Denominator: weighted average Non-redeemable common stock Basic and diluted weighted average shares outstanding, Non-redeemable common stock 8,643,813 Basic and diluted net loss per share, Non-redeemable common stock $ (3.90 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	5 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of fair value hierarchy of valuation techniques	Quoted Prices in Significant Other Significant Other Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account $ 277,547,390 $ - $ - Liabilities: Derivative warrant liabilities – public warrants $ 31,930,000 $ - $ - Derivative warrant liabilities – private warrants $ - $ - $ 17,380,000
Schedule of information regarding Level 3 fair value measurements inputs as their measurement dates	As of As of Strike price $ 10.00 $ 10.04 Contractual term (years) 1.0 1.0 Volatility 15.00 % 22.00 % Risk-free interest rate 37.00 % 0.38 % Dividend yield(per share) 0.0 % 0.0 %
Schedule of changes in the fair value of warrant liabilities	Derivative warrant liabilities at July 3, 2020 (inception) $ - Issuance of Public and Private Warrants 16,090,000 Additional warrant liabilities 1,469,100 Change in fair value of derivative warrant liabilities 31,750,900 Derivative warrant liabilities at December 31, 2020 $ 49,310,000

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	5 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information of balance sheet	As of September 30, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 279,941,343 $ - $ 279,941,343 Liabilities, redeemable non-controlling interest and stockholders’ equity Total current liabilities $ 1,102,095 $ - $ 1,102,095 Deferred underwriting commissions 9,712,500 - 9,712,500 Derivative warrant liabilities - 16,350,000 16,350,000 Total liabilities 10,814,595 16,350,000 27,164,595 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 264,126,740 (16,350,000 ) 247,776,740 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 134 163 297 Class B ordinary shares - $0.0001 par value 694 - 694 Additional paid-in-capital 5,062,928 (536,552 ) 4,526,376 Accumulated deficit (63,748 ) 536,389 472,641 Total shareholders’ equity 5,000,008 - 5,000,008 Total liabilities and shareholders’ equity $ 279,941,343 $ - $ 279,941,343
Schedule of quarterly financial information of operations and comprehensive loss	Period From July 28, 2020 (inception) Through September 30, 2020 As Previously Restatement As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (63,748 ) $ - $ (63,748 ) Other (expense) income: Change in fair value of warrant liabilities - 1,209,100 1,209,100 Financing costs - derivative warrant liabilities - (672,711 ) (672,711 ) Total other (expense) income - 536,389 536,389 Net loss $ (63,748 ) $ 536,389 $ 472,641 Basic and Diluted weighted-average Class B ordinary shares outstanding 7,066,920 - 7,275,953 Basic and Diluted net loss per Class B share $ (0.01 ) - $ 0.06
Schedule of quarterly financial information of cash flows	Period From July 28, 2020 (inception) Through September 30, 2020 As Previously Restatement As Restated Statement of Cash Flows Net loss $ (63,748 ) $ 536,389 $ 472,641 Adjustment to reconcile net loss to net cash used in operating activities 48,298 (536,389 ) (488,091 ) Net cash used in operating activities (15,450 ) - (15,450 ) Net cash used in investing activities (277,500,000 ) - (277,500,000 ) Net cash provided by financing activities 279,500,100 - 279,500,100 Net change in cash $ 1,984,650 $ - $ 1,984,650

Description of Organization, _2

Description of Organization, Business Operations and Basis of Presentation (Details) - USD ($)	1 Months Ended		5 Months Ended
	Sep. 29, 2020	Sep. 25, 2020	Dec. 31, 2020
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Over allotment price per unit	$ 10
Gross proceeds	27,500,000
Incurring additional offering costs	$ 1,500,000
Initial public offering, description		Upon the closing of the Initial Public Offering and the Private Placement on September 25, 2020, $250.0 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. In connection with the consummation of the Over-Allotment on September 29, 2020, an additional amount of $27.5 million ($10.00 per Unit), for a total of approximately $277.5 million, was placed in the Trust Account.
Fair market value, percentage			80.00%
Business combination acquires, percentage			50.00%
Net tangible assets of business combination			$ 5,000,001
Percentage of redemption			15.00%
Percentage of business combination			20.00%
Interest to pay dissolution expenses		$ 100,000
Redemption public percentage		100.00%
Business acquisition, description		In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
Operating bank account			$ 900,000
Payment sponsor expenses		$ 25,000
Sponsor [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Shares in units (in Shares)		25,000,000
Price per share (in Dollars per share)		$ 10
Generating gross proceeds		$ 250,000,000
Incurring offering costs		$ 14,400,000
Additional units, shares issued (in Shares)	2,750,000
Deferred underwriting commissions	$ 1,000,000
Private placement warrant (in Shares)		7,000,000
Percentage of business combination			100.00%
Net proceeds		$ 154,000
Warrant [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Shares in units (in Shares)	550,000
Generating gross proceeds		$ 7,000,000
Share price (in Dollars per share)		$ 1	$ 1
Warrant [Member] | Sponsor [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Deferred underwriting commissions		$ 8,800,000
Share price (in Dollars per share)			$ 10
Interest to pay dissolution expenses		$ 100,000
Warrant [Member] | IPO [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Generating gross proceeds	$ 600,000

Restatement of Financial Stat_3

Restatement of Financial Statements (Details) $ in Millions	1 Months Ended
	Sep. 25, 2020USD ($)shares
Restatement of Financial Statements (Details) [Line Items]
Warrant redemption, description.	Each Unit consists of one of the Company’s Class A ordinary shares, $0.0001 par value, and one-half of one redeemable warrant. Each whole Warrant entitles the holder to purchase one of Class A ordinary share at a price of $11.50 per share. The Warrants will expire worthless five years from the date of completion of our initial business combination. The material terms of the warrants are more fully described in Note 8—Derivative Warrant Liabilities. See revised Footnote 9 – Fair Value Measurements.
Initial Public Offering [Member]
Restatement of Financial Statements (Details) [Line Items]
Warrants issued | shares	25,000,000
Public Warrants [Member] | Private Warrants [Member]
Restatement of Financial Statements (Details) [Line Items]
Liabilities at fair value | $	$ 16.1

Restatement of Financial Stat_4

Restatement of Financial Statements (Details) - Schedule of statements of balance sheet - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Sep. 25, 2020
As Previously Reported [Member]
Balance Sheet
Total assets	$ 278,826,627	$ 279,941,343	$ 252,456,400
Total current liabilities	1,207,962	1,102,095	1,109,161
Deferred underwriting commissions	9,712,500	9,712,500	8,750,000
Derivative warrant liabilities
Total liabilities	10,920,462	10,814,595	9,859,161
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	262,906,160	264,126,740	237,597,230
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	146	134	124
Class B ordinary shares - $0.0001 par value	694	694	719
Additional paid-in-capital	6,283,496	5,062,928	5,039,923
Accumulated deficit	(1,284,331)	(63,748)	(40,757)
Total shareholders’ equity	5,000,005	5,000,008	5,000,009
Total liabilities and shareholders’ equity	278,826,627	279,941,343	252,456,400
Restatement Adjustment [Member]
Balance Sheet
Total assets
Total current liabilities
Deferred underwriting commissions
Derivative warrant liabilities	49,310,000	16,350,000	16,090,000
Total liabilities	49,310,000	16,350,000	16,090,000
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	(49,310,000)	(16,350,000)	(16,090,000)
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	493	163	161
Class B ordinary shares - $0.0001 par value
Additional paid-in-capital	32,423,118	(536,552)	672,550
Accumulated deficit	(32,423,611)	536,389	(672,711)
Total shareholders’ equity
Total liabilities and shareholders’ equity
As Restated [Member]
Balance Sheet
Total assets	278,826,627	279,941,343	252,456,400
Total current liabilities	1,207,962	1,102,095	1,109,161
Deferred underwriting commissions	9,712,500	9,712,500	8,750,000
Derivative warrant liabilities	49,310,000	16,350,000	16,090,000
Total liabilities	60,230,462	27,164,595	25,949,161
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	213,596,160	247,776,740	221,507,230
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	639	297	285
Class B ordinary shares - $0.0001 par value	694	694	719
Additional paid-in-capital	38,706,614	4,526,376	5,712,473
Accumulated deficit	(33,707,942)	472,641	(713,468)
Total shareholders’ equity	5,000,005	5,000,008	5,000,009
Total liabilities and shareholders’ equity	$ 278,826,627	$ 279,941,343	$ 252,456,400

Restatement of Financial Stat_5

Restatement of Financial Statements (Details) - Schedule of statements of balance sheet (Parentheticals) - As Restated [Member] - $ / shares	Dec. 31, 2020	Sep. 30, 2020	Sep. 25, 2020
Condensed Financial Statements, Captions [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Class A Ordinary Shares [Member]
Condensed Financial Statements, Captions [Line Items]
Common stock subject to possible redemption, par value	0.0001	0.0001	0.0001
Common stock, par value	0.0001	0.0001	0.0001
Class B Ordinary Shares [Member]
Condensed Financial Statements, Captions [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001

Restatement of Financial Stat_6

Restatement of Financial Statements (Details) - Schedule of statements of operations - USD ($)	2 Months Ended	5 Months Ended
	Sep. 30, 2020	Dec. 31, 2020
As Previously Reported [Member]
Statement of Operations and Comprehensive Loss
Loss from operations	$ (63,748)	$ (1,332,873)
Other (expense) income:
Change in fair value of derivative warrant liabilities
Financing costs - derivative warrant liabilities
Interest earned on investments held in Trust Account		48,542
Total other (expense) income		48,542
Net loss	$ (63,748)	$ (1,284,331)
Basic and diluted weighted average shares outstanding (in Shares)	7,066,920
Basic and diluted net income per share (in Dollars per share)	$ (0.01)
As Previously Reported [Member] | Class A Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)		26,276,074
Basic and diluted net income per share (in Dollars per share)		$ 0
As Previously Reported [Member] | Class B Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)		7,561,720
Basic and diluted net income per share (in Dollars per share)		$ (0.18)
Restatement Adjustment [Member]
Statement of Operations and Comprehensive Loss
Loss from operations
Other (expense) income:
Change in fair value of derivative warrant liabilities	(1,209,100)	(31,750,900)
Financing costs - derivative warrant liabilities	672,711	(672,711)
Interest earned on investments held in Trust Account
Total other (expense) income		(32,423,611)
Net loss	$ 536,389	$ (32,423,611)
Basic and diluted weighted average shares outstanding (in Shares)
Basic and diluted net income per share (in Dollars per share)
Restatement Adjustment [Member] | Class A Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)
Basic and diluted net income per share (in Dollars per share)
Restatement Adjustment [Member] | Class B Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)
Basic and diluted net income per share (in Dollars per share)
As Restated [Member]
Statement of Operations and Comprehensive Loss
Loss from operations	$ (63,748)	$ (1,332,873)
Other (expense) income:
Change in fair value of derivative warrant liabilities	(1,209,100)	(31,750,900)
Financing costs - derivative warrant liabilities	672,711	(672,711)
Interest earned on investments held in Trust Account		48,542
Total other (expense) income		(32,375,069)
Net loss	$ 472,641	$ (33,707,942)
Basic and diluted weighted average shares outstanding (in Shares)	7,275,953
Basic and diluted net income per share (in Dollars per share)	$ 0.06
As Restated [Member] | Class A Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)		25,913,041
Basic and diluted net income per share (in Dollars per share)		$ 0
As Restated [Member] | Class B Ordinary Shares [Member]
Other (expense) income:
Basic and diluted weighted average shares outstanding (in Shares)		8,643,813
Basic and diluted net income per share (in Dollars per share)		$ (3.90)

Restatement of Financial Stat_7

Restatement of Financial Statements (Details) - Schedule of statements of cash flows - USD ($)	2 Months Ended	5 Months Ended
	Sep. 30, 2020	Dec. 31, 2020
As Previously Reported [Member]
Statement of Cash Flows
Net loss	$ (63,748)	$ (1,284,331)
Adjustment to reconcile net loss to net cash used in operating activities	48,298	740,604
Net cash used in operating activities	(15,450)	(543,727)
Net cash used in investing activities	(277,500,000)	(277,500,000)
Net cash provided by financing activities	279,500,100	278,917,609
Net change in cash	1,984,650	873,882
Restatement Adjustment [Member]
Statement of Cash Flows
Net loss	536,389	(32,423,611)
Adjustment to reconcile net loss to net cash used in operating activities	(536,389)	32,423,611
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net change in cash
As Restated [Member]
Statement of Cash Flows
Net loss	472,641	(33,707,942)
Adjustment to reconcile net loss to net cash used in operating activities	(488,091)	33,164,215
Net cash used in operating activities	(15,450)	(543,727)
Net cash used in investing activities	(277,500,000)	(277,500,000)
Net cash provided by financing activities	279,500,100	278,917,609
Net change in cash	$ 1,984,650	$ 873,882

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	5 Months Ended
	Dec. 31, 2020USD ($)shares
Summary of Significant Accounting Policies (Details) [Line Items]
Cash equivalents held in money market funds (in Dollars) | $	$ 277,500,000
Maturity days	185 days
Federal depository insurance coverage limit (in Dollars) | $	$ 250,000
U.S. Treasury securities [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Maturity days	185 days
Private Placement [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrants sold in public offering and private placement to purchase an aggregate shares	21,425,000
Warrant [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrants to purchase ordinary shares issued	(13,875,000)
Class A Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrants to purchase ordinary shares issued	6,390,384
Shares subject to possible redemption	21,359,616

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted loss per common share	5 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Numerator: Earnings allocable to Common stock subject to possible redemption
Income from investments held in Trust Account	$ 37,362
Less: Company’s portion available to be withdrawn to pay taxes
Net income attributable	$ 37,362
Denominator: Weighted average Class A common stock subject to possible redemption
Basic and diluted weighted average shares outstanding (in Shares) | shares	25,913,041
Basic and diluted net income per share (in Dollars per share) | $ / shares	$ 0
Numerator: Net Loss minus Net Earnings
Net loss	$ (33,707,942)
Less: Net income allocable to Class A common stock subject to possible redemption	37,362
Non-redeemable net loss	$ (33,745,304)
Denominator: weighted average Non-redeemable common stock
Basic and diluted weighted average shares outstanding, Non-redeemable common stock (in Shares) | shares	8,643,813
Basic and diluted net loss per share, Non-redeemable common stock (in Dollars per share) | $ / shares	$ (3.90)

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		5 Months Ended
	Sep. 29, 2020	Sep. 25, 2020	Dec. 31, 2020
Initial Public Offering [Member]
Initial Public Offering (Details) [Line Items]
Units in shares (in Shares)		25,000,000	3,750,000
Per unit price (in Dollars per share)		$ 10
Gross proceeds		$ 250
Offering costs		14.4
Deferred underwriting commissions		$ 8.8
Description of public warrant			Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8).
Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Units in shares (in Shares)	2,750,000
Per unit price (in Dollars per share)	$ 10
Gross proceeds	$ 27.5
Offering costs	1.5
Deferred underwriting commissions	$ 1
Class A Ordinary Shares [Member]
Initial Public Offering (Details) [Line Items]
Per unit price (in Dollars per share)			$ 12
Exercise price per share (in Dollars per share)	$ 11.50

Private Placement (Details)

Private Placement (Details) - USD ($)	1 Months Ended		5 Months Ended
	Sep. 29, 2020	Sep. 25, 2020	Dec. 31, 2020
Private Placement (Details) [Line Items]
Gross proceeds			$ 7,550,000
Gross proceeds			$ 277,500,000
Sponsors [Member]
Private Placement (Details) [Line Items]
Number of shares purchased		25,000,000
Price per share		$ 10
Private Placement Warrants [Member]
Private Placement (Details) [Line Items]
Number of shares purchased		7,000,000
Price per share		$ 1
Gross proceeds	$ 600,000
Over-Allotment Option [Member]
Private Placement (Details) [Line Items]
Number of shares purchased	2,750,000
Price per share	$ 10
Gross proceeds		$ 7,000,000
Private Placement Warrants [Member] | Sponsors [Member]
Private Placement (Details) [Line Items]
Number of shares purchased	550,000
Class A Ordinary Shares [Member]
Private Placement (Details) [Line Items]
Price per share			$ 12
Shares issued per share			$ 11.50

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Sep. 03, 2020	Aug. 03, 2020	Sep. 29, 2020	Sep. 25, 2020	Sep. 18, 2020	Dec. 31, 2020
Related Party Transactions (Details) [Line Items]
Percentage of issued and outstanding shares					20.00%
Office space (in Dollars)						$ 10,000
Related party expenses (in Dollars)						33,000
Accrued expenses related parties (in Dollars)
Founder shares [Member]
Related Party Transactions (Details) [Line Items]
Issuance of amount (in Dollars)		$ 25,000
Transferred shares	35,000
Issuance of shares					937,500
Over-Allotment Option [Member]
Related Party Transactions (Details) [Line Items]
Issuance of shares			2,750,000
Forfeited shares			250,000
Share price per share (in Dollars per share)			$ 10
Initial Public Offering [Member]
Related Party Transactions (Details) [Line Items]
Issuance of shares				25,000,000		3,750,000
Share price per share (in Dollars per share)				$ 10
Description of related party loans		the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is non-interest bearing, unsecured and due upon the closing of the Initial Public Offering. As of December 31, 2020, the Company borrowed approximately $154,000 under the Note. The Note was repaid in full on October 1, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans.
Warrant [Member]
Related Party Transactions (Details) [Line Items]
Issuance of shares			550,000
Share price (in Dollars per share)				$ 1		$ 1
Class B Ordinary Shares [Member]
Related Party Transactions (Details) [Line Items]
Issuance of shares		8,625,000
Common stock, shares, outstanding					7,187,500	6,937,500
Forfeited shares					937,500
Class B Ordinary Shares [Member] | Founder shares [Member]
Related Party Transactions (Details) [Line Items]
Issuance of shares					1,437,500
Common stock, shares, outstanding					7,187,500
Class A ordinary shares [Member]
Related Party Transactions (Details) [Line Items]
Common stock, shares, outstanding						6,390,384
Share price per share (in Dollars per share)						$ 12
Share price (in Dollars per share)			$ 11.50

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	1 Months Ended		5 Months Ended
	Sep. 29, 2020	Sep. 25, 2020	Dec. 31, 2020
Initial Public Offering [Member]
Commitments and Contingencies (Details) [Line Items]
Purchase shares		25,000,000	3,750,000
Over-Allotment Units [Member]
Commitments and Contingencies (Details) [Line Items]
Purchase shares	2,750,000
Additional units, shares issued	2,750,000
Underwriting Agreement [Member] | Initial Public Offering [Member]
Commitments and Contingencies (Details) [Line Items]
Description of underwriting agreement		the underwriters were entitled to an underwriting discount of $0.20 per unit, or $5.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $8.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions
Amount of underwriting discount	$ 0.6
Deferred fee	$ 1

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Details)	5 Months Ended
	Dec. 31, 2020USD ($)$ / shares
Derivative Warrant Liabilities (Details) [Line Items]
Warrants exercise price | $ / shares	$ 11.50
Warrants term	5 years
Initial business combination, description	In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
Description of Location of Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments in Financial Statements	30 days
Private Placement Warrants [Member]
Derivative Warrant Liabilities (Details) [Line Items]
Warrants outstanding | $	$ 7,550,000
Public Warrants [Member]
Derivative Warrant Liabilities (Details) [Line Items]
Warrants outstanding | $	$ 13,875,000
Class A Ordinary Shares [Member]
Derivative Warrant Liabilities (Details) [Line Items]
Redemption of warrants, description	Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants: ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; and ● if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and ● if the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.
Redemption of warrants price per share | $ / shares	$ 0.361
Class A Ordinary Shares [Member] | Private Placement Warrants [Member]
Derivative Warrant Liabilities (Details) [Line Items]
Redemption of warrants, description	Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants): ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

Shareholders_ Equity (Details)

Shareholders’ Equity (Details) - $ / shares	Sep. 03, 2020	Sep. 29, 2020	Sep. 18, 2020	Dec. 31, 2020	Aug. 03, 2020
Shareholders’ Equity (Details) [Line Items]
Option term				185 days
Conversion basis percentage				20.00%
Preferred stock, shares authorized				5,000,000
Preferred stock par value (in Dollars per share)				$ 0.0001
Over-Allotment Option [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares subject to forfeiture		250,000
Option term		45 days
Founder Shares [Member]
Shareholders’ Equity (Details) [Line Items]
Transferred shares	35,000
Class A Ordinary Shares [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares authorized				500,000,000
Ordinary shares par value (in Dollars per share)				$ 0.0001
Ordinary shares, shares issued				6,390,384
Ordinary shares, shares outstanding				6,390,384
Ordinary shares subject to possible redemption				21,359,616
Class A Ordinary Shares [Member] | Holder [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares, shares issued				27,750,000
Ordinary shares, shares outstanding				27,750,000
Class B Ordinary Shares [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares authorized				50,000,000
Ordinary shares par value (in Dollars per share)				$ 0.0001
Ordinary shares, shares issued				6,937,500	8,625,000
Ordinary shares, shares outstanding			7,187,500	6,937,500
Consideration shares			1,437,500
Ordinary shares subject to forfeiture			937,500
Issued and outstanding ordinary shares percentage			20.00%
Class B Ordinary Shares [Member] | Founder Shares [Member]
Shareholders’ Equity (Details) [Line Items]
Ordinary shares, shares outstanding			7,187,500

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	1 Months Ended	5 Months Ended
	Sep. 25, 2020	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Balance in investments held in trust account		$ 1,000
Derivative warrant liabilities	$ 16,090,000
Change in fair value of derivative warrant liabilities		$ 33,220,000

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of fair value hierarchy of valuation techniques	5 Months Ended
	Dec. 31, 2020USD ($)
Quoted Prices in Active Markets (Level 1) [Member]
Assets:
Investments held in Trust Account	$ 277,547,390
Liabilities:
Derivative warrant liabilities – public warrants	31,930,000
Derivative warrant liabilities – private warrants
Significant Other Observable Inputs (Level 2) [Member]
Assets:
Investments held in Trust Account
Liabilities:
Derivative warrant liabilities – public warrants
Derivative warrant liabilities – private warrants
Significant Other Unobservable Inputs (Level 3) [Member]
Assets:
Investments held in Trust Account
Liabilities:
Derivative warrant liabilities – public warrants
Derivative warrant liabilities – private warrants	$ 17,380,000

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of information regarding Level 3 fair value measurements inputs as their measurement dates - $ / shares	2 Months Ended	5 Months Ended
	Sep. 25, 2020	Dec. 31, 2020
Schedule of information regarding Level 3 fair value measurements inputs as their measurement dates [Abstract]
Strike price (in Dollars per share)	$ 10	$ 10.04
Contractual term (years)	1 year	1 year
Volatility	15.00%	22.00%
Risk-free interest rate	37.00%	0.38%
Dividend yield(per share)	0.00%	0.00%

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities	5 Months Ended
	Dec. 31, 2020USD ($)
Schedule of changes in the fair value of warrant liabilities [Abstract]
Derivative warrant liabilities at beginning
Issuance of Public and Private Warrants	16,090,000
Additional warrant liabilities	1,469,100
Change in fair value of derivative warrant liabilities	31,750,900
Derivative warrant liabilities at ending	$ 49,310,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Jan. 11, 2021USD ($)$ / sharesshares
Subsequent Events (Details) [Line Items]
Business combination consideration, description	In the Merger, each share of common stock of Proterra, other than shares to be cancelled or dissenting shares, will be converted into the right to receive 0.8925 shares of ArcLight Common Stock. In the event that the closing sale price of ArcLight Common Stock exceeds certain price thresholds for 20 out of any 30 consecutive trading days during the first five years following the closing of the Business Combination, up to an additional 22,809,500 shares of ArcLight Common Stock may be issued to the parties that were holders of Proterra Common Stock immediately prior to the closing of the Business Combination.
Aggregate shares of common stock | shares	41,500,000
Purchase price per share | $ / shares	$ 10
Aggregate gross proceeds | $	$ 415,000,000
Description of sponsor letter agreement	Concurrently with the execution of the Merger Agreement, the Sponsor entered into the Sponsor Letter Agreement (the “Sponsor Letter Agreement”), pursuant to which the parties agreed (i) to certain vesting and forfeiture terms with respect to 10% of the Company’s Common Stock beneficially owned by the Sponsor immediately following the closing, (ii) to certain lock-up provisions with respect to shares of Company Common Stock following the Merger (which provisions were subsequently amended on February 2, 2021) and (iii) to cause the Company’s designee to the ArcLight board of directors to resign in the event the Sponsor disposes of 50% or more of the ArcLight Common Stock held beneficially by the Sponsor as of the closing of the Business Combination.

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of balance sheet - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Sep. 25, 2020
As Previously Reported [Member]
Balance Sheet
Total assets	$ 278,826,627	$ 279,941,343	$ 252,456,400
Liabilities, redeemable non-controlling interest and stockholders’ equity
Total current liabilities	1,207,962	1,102,095	1,109,161
Deferred underwriting commissions	9,712,500	9,712,500	8,750,000
Derivative warrant liabilities
Total liabilities	10,920,462	10,814,595	9,859,161
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	262,906,160	264,126,740	237,597,230
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	146	134	124
Class B ordinary shares - $0.0001 par value	694	694	719
Additional paid-in-capital	6,283,496	5,062,928	5,039,923
Accumulated deficit	(1,284,331)	(63,748)	(40,757)
Total shareholders’ equity	5,000,005	5,000,008	5,000,009
Total liabilities and shareholders’ equity	278,826,627	279,941,343	252,456,400
Restatement Adjustment [Member]
Balance Sheet
Total assets
Liabilities, redeemable non-controlling interest and stockholders’ equity
Total current liabilities
Deferred underwriting commissions
Derivative warrant liabilities	49,310,000	16,350,000	16,090,000
Total liabilities	49,310,000	16,350,000	16,090,000
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	(49,310,000)	(16,350,000)	(16,090,000)
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	493	163	161
Class B ordinary shares - $0.0001 par value
Additional paid-in-capital	32,423,118	(536,552)	672,550
Accumulated deficit	(32,423,611)	536,389	(672,711)
Total shareholders’ equity
Total liabilities and shareholders’ equity
As Restated [Member]
Balance Sheet
Total assets	278,826,627	279,941,343	252,456,400
Liabilities, redeemable non-controlling interest and stockholders’ equity
Total current liabilities	1,207,962	1,102,095	1,109,161
Deferred underwriting commissions	9,712,500	9,712,500	8,750,000
Derivative warrant liabilities	49,310,000	16,350,000	16,090,000
Total liabilities	60,230,462	27,164,595	25,949,161
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	213,596,160	247,776,740	221,507,230
Shareholders’ equity
Preference shares - $0.0001 par value
Class A ordinary shares - $0.0001 par value	639	297	285
Class B ordinary shares - $0.0001 par value	694	694	719
Additional paid-in-capital	38,706,614	4,526,376	5,712,473
Accumulated deficit	(33,707,942)	472,641	(713,468)
Total shareholders’ equity	5,000,005	5,000,008	5,000,009
Total liabilities and shareholders’ equity	$ 278,826,627	$ 279,941,343	$ 252,456,400

Quarterly Financial Informati_4

Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of balance sheet (Parentheticals) - As Restated [Member] - $ / shares	Dec. 31, 2020	Sep. 30, 2020	Sep. 25, 2020
Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of balance sheet (Parentheticals) [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Class A Ordinary Shares [Member]
Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of balance sheet (Parentheticals) [Line Items]
Common stock subject to possible redemption, par value	0.0001	0.0001	0.0001
Common stock, par value	0.0001	0.0001	0.0001
Class B Ordinary Shares [Member]
Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of balance sheet (Parentheticals) [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001

Quarterly Financial Informati_5

Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of operations and comprehensive loss - USD ($)	2 Months Ended	5 Months Ended
	Sep. 30, 2020	Dec. 31, 2020
As Previously Reported [Member]
Statement of Operations and Comprehensive Loss
Loss from operations	$ (63,748)	$ (1,332,873)
Other (expense) income:
Change in fair value of warrant liabilities
Financing costs - derivative warrant liabilities
Total other (expense) income
Net loss	$ (63,748)	(1,284,331)
Basic and Diluted weighted-average Class B ordinary shares outstanding (in Shares)	7,066,920
Basic and Diluted net loss per Class B share (in Dollars per share)	$ (0.01)
Restatement Adjustment [Member]
Statement of Operations and Comprehensive Loss
Loss from operations
Other (expense) income:
Change in fair value of warrant liabilities	1,209,100	31,750,900
Financing costs - derivative warrant liabilities	(672,711)	672,711
Total other (expense) income	536,389
Net loss	$ 536,389	(32,423,611)
Basic and Diluted weighted-average Class B ordinary shares outstanding (in Shares)
Basic and Diluted net loss per Class B share (in Dollars per share)
As Restated [Member]
Statement of Operations and Comprehensive Loss
Loss from operations	$ (63,748)	(1,332,873)
Other (expense) income:
Change in fair value of warrant liabilities	1,209,100	31,750,900
Financing costs - derivative warrant liabilities	(672,711)	672,711
Total other (expense) income	536,389
Net loss	$ 472,641	$ (33,707,942)
Basic and Diluted weighted-average Class B ordinary shares outstanding (in Shares)	7,275,953
Basic and Diluted net loss per Class B share (in Dollars per share)	$ 0.06

Quarterly Financial Informati_6

Quarterly Financial Information (Unaudited) (Details) - Schedule of quarterly financial information of cash flows - USD ($)	2 Months Ended	5 Months Ended
	Sep. 30, 2020	Dec. 31, 2020
As Previously Reported [Member]
Statement of Cash Flows
Net loss	$ (63,748)	$ (1,284,331)
Adjustment to reconcile net loss to net cash used in operating activities	48,298	740,604
Net cash used in operating activities	(15,450)	(543,727)
Net cash used in investing activities	(277,500,000)	(277,500,000)
Net cash provided by financing activities	279,500,100	278,917,609
Net change in cash	1,984,650	873,882
Restatement Adjustment [Member]
Statement of Cash Flows
Net loss	536,389	(32,423,611)
Adjustment to reconcile net loss to net cash used in operating activities	(536,389)	32,423,611
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net change in cash
As Restated [Member]
Statement of Cash Flows
Net loss	472,641	(33,707,942)
Adjustment to reconcile net loss to net cash used in operating activities	(488,091)	33,164,215
Net cash used in operating activities	(15,450)	(543,727)
Net cash used in investing activities	(277,500,000)	(277,500,000)
Net cash provided by financing activities	279,500,100	278,917,609
Net change in cash	$ 1,984,650	$ 873,882